Newsfeeds - Spark Newswire

3 minute read

Who’s Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In Person

Today, 10:54 AM

This year’s edition of the Benzinga Psychedelics Capital Conference, THE place to be for those interested or already involved in the space, will take place on April 13, following our established Cannabis Capital Confere

BWVI

6 minute read

10 Psychedelics CEOs To Pay Attention To In 2022

By Javier Hasse

Today, 10:54 AM

By Javier Hasse and Aaron Bry. 2020 and 2021 were defining years for the burgeoning psychedelics industry. In 2021 alone, more than $730 million were invested into various psychedelic companies, both private and public.

ATAI

1 minute read

Benchmark Downgrades Trillium Therapeutics to Hold

By Benzinga Newsdesk

Today, 10:54 AM

Benchmark analyst Aydin Huseynov downgrades Trillium Therapeutics (NASDAQ:TRIL) from Buy to Hold.

TRIL

2 minute read

Legal
News

Trillium Therapeutics Receives Final Court Order Approving Arrangement

By Benzinga Newsdesk

Today, 10:54 AM

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is pleased to

PFE

6 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For August 24, 2021

By Benzinga Insights

Today, 10:54 AM

AGCO

1 minute read

Craig-Hallum Downgrades Trillium Therapeutics to Hold, Lowers Price Target to $18.5

By Benzinga Newsdesk

Today, 10:54 AM

Craig-Hallum analyst Robin Garner downgrades Trillium Therapeutics (NASDAQ:TRIL) from Buy to Hold and lowers the price target from $21 to $18.5.

TRIL

5 minute read

60 Biggest Movers From Yesterday

By Lisa Levin

Today, 10:54 AM

Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be acquired by Pfizer for $18.50 per share, implying an equity value of $2.26 billion.

ABVC

1 minute read

JMP Securities Downgrades Trillium Therapeutics to Market Perform

By Benzinga Newsdesk

Today, 10:54 AM

JMP Securities analyst Reni Benjamin downgrades Trillium Therapeutics (NASDAQ:TRIL) from Market Outperform to Market Perform.

TRIL

2 minute read

Mid-Afternoon Market Update: Dow Gains 270 Points; Vivos Therapeutics Shares Spike Higher

By Lisa Levin

Today, 10:54 AM

Toward the end of trading Monday, the Dow traded up 0.77% to 35,392.00 while the NASDAQ rose 1.64% to 14,956.54. The S&P also rose, gaining 1.01% to 4,486.66.

CIO

1 minute read

Jim Cramer Thinks More Acquisitions From Pfizer Are Coming, Reveals What Similar Type Of Stocks To Watch

By Adam Eckert

Today, 10:54 AM

Pfizer Inc. (NYSE: PFE) announced Monday that it entered into a definitive agreement to acquire Trillium Therapeutics Inc (NASDAQ: TRIL) for an implied equity value of $2.26 billion, or $18.50 per share.

PFE